Our leadership team is a highly successful and uniquely experienced group of clinicians, scientists, corporate executives, and investment professionals.
Our focus: deliver novel antiviral medicines to the right people at the right time, to significantly reduce morbidity, mortality, and costs associated with viral infections among vulnerable populations.
Altesa’s world-class scientific founders have already developed medicines that have saved – and are continuing to save – countless lives. Specifically, Altesa’s founders have invented emtricitabine (Emtriva®), which combats HIV/AIDS, and molnupiravir (Lagevrio®), which prevents hospitalization and death from COVID-19. Altesa’s clinical, regulatory, and scientific teams also have helped develop and market medicines such as brincidofovir (Tembexa®) to treat smallpox, and enfuvirtide (Fuzeon®), the first HIV fusion inhibitor to treat people living with HIV/AIDS.
Alan Parr, PharmD, PhD
- Former Vice President of Biopharmaceutics, GlaxoSmithKline
BOARD OF DIRECTORS
SCIENTIFIC ADVISORY BOARD
George R. Painter, PhD
James F. Donohue, MD
- Former Professor of Medicine, Division of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill
- Recipient of the “Breathing for Life Award” from the American Thoracic Society, the highest honor given for philanthropy, scientific achievement and commitment to mentorship
- Has led trials for the most commonly used inhaled therapies for COPD and asthma
Dennis C. Liotta, PhD
- Samuel Candler Dobbs Professor, Department of Chemistry, Emory University
- Professor, Department of Pharmacology and Chemical Biology, Emory University School of Medicine
- Co-founder, Pharmasset
- Co-founder, DRIVE and Emory Institute for Drug Development
- Co-inventor emtricitabine and lamivudine
MeiLan K. Han, MD, MS
Richard Whitley, MD
- Professor of Microbiology, Medicine and Neurosurgery, University of Alabama, Birmingham
- Past President of the Infectious Diseases Society of America (IDSA)
- Inaugural recipient of the Distinguished Clinical Research Scholar and Educator in Residence at the NIH Clinical Center.
- Recipient of the 2020 National Foundation for Infectious Diseases John P. Utz Leadership Award
Partners / Collaborators
Altesa has an innovative relationship with Drug Innovation Ventures at Emory (DRIVE),formed by Emory University to discover and advance new medicines against viral infections. DRIVE is both a key scientific collaborator and a founding shareholder of Altesa.
George R. Painter, PhD, and Dennis C. Liotta, PhD are Altesa scientific co-founders and serve on the Scientific Advisory Board. Drs. Painter and Liotta were instrumental, respectively, in the discovery and successful commercialization of molnupiravir, which treats the virus causing COVID-19, and emtricitabine, which is one of the most widely used medicines for prevention and treatment of HIV/AIDS.
The unprecedented partnership agreement between Altesa and DRIVE led to the licensing of a late-stage preclinical, antiviral drug (ALT-2023) in January 2022. ALT-2023 is a broad-spectrum nucleoside analog that is active against most enteroviruses and flaviviruses, including rhinovirus and hepatitis C. Altesa has a unique, preferred relationship with DRIVE/Emory, giving Altesa exclusive access to up to five additional DRIVE molecules to combat other viral respiratory diseases.